产品
编 号：F239941
分子式：C21H23Cl2N3O3S
分子量：468.4
分子式：C21H23Cl2N3O3S
分子量：468.4
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 193012-35-0
产品详情
生物活性：
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes.
体内研究：
FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level.FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance.Animal Model:db/db Mice
Dosage:0.1~10 mg/kg
Administration:P.o.
Result:Improved the impaired glucose tolerance.
Animal Model:db/db Mice
Dosage:0.32~3.2 mg/kg
Administration:P.o.
Result:Dose-dependently reduced plasma glucose level.
体外研究：
FK614 (0.1~10000 nM; 24 hours; CV-1 cells) activates PPARγ-dependent transcription in a concentration-dependent manner. FK614 (0~0.1 μM; 5 days; 3T3-L1 adipocytes) makes triglyceride content increased in a concentration-dependent manner. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is an insulin sensitizer potentially for treatment of postherpetic neuralgia. FK614 is a non-TZD insulin sensitizer.
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes.
体内研究：
FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level.FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance.Animal Model:db/db Mice
Dosage:0.1~10 mg/kg
Administration:P.o.
Result:Improved the impaired glucose tolerance.
Animal Model:db/db Mice
Dosage:0.32~3.2 mg/kg
Administration:P.o.
Result:Dose-dependently reduced plasma glucose level.
体外研究：
FK614 (0.1~10000 nM; 24 hours; CV-1 cells) activates PPARγ-dependent transcription in a concentration-dependent manner. FK614 (0~0.1 μM; 5 days; 3T3-L1 adipocytes) makes triglyceride content increased in a concentration-dependent manner. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is an insulin sensitizer potentially for treatment of postherpetic neuralgia. FK614 is a non-TZD insulin sensitizer.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备